SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Siemens' new CT gets FDA nod New opportunity for freestanding ERs

ASTRO 2014 - resounding success The 2014 show and conference brought a lot to the table

ASTRO and AANS team-up on SRS patient registry The stereotactic radiosurgery patient registry will utilize 30 participating facilities

Varian rolls out InSightive Analytics at ASTRO, an interactive visualization solution The tool gives users of the ARIA information system powerful data analysis capabilities

Single fraction is just as good at multiple fraction radiation therapy ASTRO presents breakthrough study

Siemens shows MR & CT solutions at ASTRO optimized for radiation oncology The company innovates advances in the practice of radiation therapy (RT)

Accuray puts technology on display at ASTRO The company showcased the latest in TomoTherapy and CyberKnife technology

Varian's software support for Siemens' Modulated Arc (mARC) highlighted at ASTRO Varian treatment planning software now available to oncology facilities using Siemens LINACs

The shifting medical practice may decrease access to care More patients insured but doctors are at full capacity

MEDICA 2014: robotics in the cardiology field Events highlight new advances

Bracco gets FDA nod to expand Multihance indications

by Brendon Nafziger , DOTmed News Associate Editor
Bracco Diagnostics Inc. said Friday it received Food and Drug Administration approval to expand the indications of an MRI imaging agent used to detect brain tumors to now cover certain types of arterial disease.

Bracco said the drug, Multihance (gadobenate dimeglumine), now has been expanded for use in magnetic resonance angiographies to help diagnose stenosis in the renal and aorto-ilio-femoral arteries. The gadolinium-based contrast agent was originally approved by the FDA in 2004 for MRI scans of the central nervous system in children and adults.

Story Continues Below Advertisement

Learn more about McKesson's solutions for radiology

McKesson Enterprise Medical Imaging Solutions Help Enhance Your Financial, Clinical & Operational Effectiveness. Learn more about McKesson solutions for radiology at McKesson.com/medicalimaging



The company said the approval came about after Bracco conducted two large, multi-center, prospective trials on the new indication.

As with other GBCAs, Multihance carries a black box warning label because of the risk of nephrogenic systemic fibrosis, believed to be an extremely rare side effect for patients with kidney problems who receive GBCA injections. However, in a statement, Dr. Alberto Spinazzi, senior vice president of regulatory affairs with Bracco, said Multihance carries a "strong record of safety" and has been administered more than 14 million times.

"Multihance has long been distinguished in the MRI of the CNS as a gadolinium-based contrast agent characterized by a strong increase in relaxivity in any medium containing serum proteins, contributing to increased contrast-to-noise ratio and lesion-to-brain ratio and improved visualization," he said.

Bracco Group is headquartered in Milan, Italy.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED